Next Potential Big ADC Player? Korean Firms Take It Up A Notch
Most Assets Still Early Stage
Executive Summary
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
You may also be interested in...
New Korea Commission Needs Status To Function As Control Tower: Industry
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
Global Health Leaders Highlight Pandemic Preparedness
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Are Korean Biopharma Alliances Recovering After Gloomy Year?
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.